BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Aegis Therapeutics, LLC Awarded Patent for GLP-1 Peptide Drug Formulations Suitable for Metered Nasal Spray and Oral Delivery


8/16/2011 8:05:01 AM

SAN DIEGO, CA--(Marketwire - August 16, 2011) -

Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 7,998,927 providing broad protection for stabilized formulations of GLP-1 peptide analogs suitable for all routes of administration including the non-invasive oral or metered nasal spray delivery routes, or injection. Examples of GLP-1 analogs include Novo Nordisk's Liraglutide (Victoza®), Lilly-Amylin's Exendin-4 (Byetta®), and Sanofi-aventis' Lixisenatide, among others, representing a new class of highly effective anti-diabetes drugs that appear to offer additional weight-loss benefits as well. GLP-1 drugs have gained quick acceptance in a rapidly growing multibillion dollar worldwide market.

All currently approved GLP-1 drug formulations require injection once or twice per day. In contrast, preclinical studies of Aegis' Intravail®/ProTek®-based formulations of a number of different GLP-1 analogs have demonstrated excellent oral or nasal bioavailability offering the prospect of a "first in class" non-injectable GLP-1 analog. ProTek® excipients also reduce or eliminate unwanted immunogenicity of peptide and protein drugs. Non-injectable dosage forms of previously injectable-only drugs provide greater patient convenience and acceptance, improved compliance, and avoidance of needle-stick injury and disposal problems associated with the use of needles, paving the way to increased market share and substantial growth in overall product sales. Aegis will seek one or more partners for its non-invasive GLP-1 delivery technology.

About Aegis Therapeutics

Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability. Our ProTek® technology allows creation of easily manufacturable, and stable aqueous or lyophilized dosage forms that maintain product integrity and reduce unwanted immunogenicity of protein and peptide therapeutics. ProTek® technology is applicable to injectable, intranasal, oral, and other dosage forms.

For more information about Aegis, please visit: http://www.aegisthera.com.


Contact:
Ralph Barry
Chief Business Officer
Aegis Therapeutics LLC
1-858-618-1400 Ext. 102
Email: Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES